Cytogenetics and molecular genetics of cancer of the prostate

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 115, Issue 3, 2002, Pages 150-156

  Brothman, Arthur R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytogenetics; Genetics; Molecular genetics; Prostate cancer; Review

Indexed keywords

PROTEIN; STEROID 5ALPHA REDUCTASE;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CHROMOSOME; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FAMILIAL CANCER; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; MOLECULAR GENETICS; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; ANIMAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MALE; MOUSE; PROSTATE TUMOR; REVIEW;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0037202201     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.10694     Document Type: Article

References (85)

1. Abate-Shen C, Shen MM. 2000. Molecular genetics of prostate cancer. Genes Dev 14:2410-2434.
2. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB. 1994. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002.
3. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schroder FH, van der Kwast TH, Bosman FT, van Dekken H. 1997. Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are revolved in metastasis to the bone. Lab Invest 77:437-448.
4. Atkin NB, Baker MC. 1985. Chromosome 10 deletion in carcinoma of the prostate [Letter]. N Engl J Med 312:315.
5. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. 1994. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: Association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 58:721729.
6. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC. 1994. Trisomy 7: A potential cytogenetic marker of human prostate cancer progression. Genes Chromosom Cancer 9:19-27.
7. Bassett DE Jr, Eisen MB, Boguski MS. 1999. Gene expression informatics: It's all in your mind. Nature Genet 21:51-55.
8. Bergerheim US, Kunimi K, Collins VP, Ekman P. 1991. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosom Cancer 3:215-220.
9. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ. 2000. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67:82-91.
10. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Bellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cussenot O. 1998. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62:1416-1424.
11. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. 1993. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873.
12. Bratt O. 2000. Hereditary prostate cancer. BJU Int 85:588-598.
13. Brothman AR, Peehl DM, Patel AM, McNeal JE. 1990. Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795-3803.
14. Brothman AR, Maxwell TM, Cui J, Deubler DA, Zhu XL. 1999. Chromosomal clues to the development of prostate tumors. Prostate 38:303-312.
15. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. 1999. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806.
16. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA. 1987. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11:327-337.
17. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D. 1997. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997-5000.
18. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J. 2002. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genet 30:181-184.
19. Carter HB, Piantadosi S, Isaacs JT. 1990. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143:742-746.
20. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. 1992. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367-3371.
21. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. 1993. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 150:797-802.
22. Chen C. 2001. Risk of prostate cancer in relation to polymorphisms of metabolic genes. Epidemiol Rev 23:30-35.
23. Cher ML, Ito T, Weidner N, Carroll PR, Jensen KH. 1995. Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 153:249-254.
24. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. 1996. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102.
25. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. 1996. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 56:1142-1145.
26. Cui J, Deubler DA, Rohr LR, Zhu XL, Maxwell TM, Changus JE, Brothman AR. 1998. Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet Cytogenet 107:51-60.
27. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. 2001. Hypermethylation of the Caveolin-1 gene promoter in prostate cancer. Prostate 46:249-256.
28. Dahiya R, McCarville J, Hu W, Lee C, Chui RM, Kaur G, Deng G. 1997. Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int J Cancer 71:20-25.
29. Dai Q, Deubler DA, Maxwell TM, Zhu XL, Cui J, Rohr LR, Stephenson RA, Brothman AR. 2001. A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1. Genomics 71:324-329.
30. Dasari VK, Deng D, Perinchery G, Yeh CC, Dahiya R. 2002. DNA methylation regulates the expression of Y chromosome specific genes in prostate cancer. J Urol 167:335-338.
31. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. 1995. KA11, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 [see Comments]. Science 268:884-886.
32. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. 1996. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2:1039-1048.
33. Esteller M, Corn PG, Baylin SB, Herman JG. 2001. A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229.
34. Etzioni R, Cha R, Feuer EJ, Davidov O. 1998. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 148:775-785.
35. Foster CS, Bostwick DG, Bonkhoff H, Damber JE, van der Kwast T, Montironi R, Sakr WA. 2000. Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol Suppl 205:19-43.
36. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ. 1993. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 53:2723-2727.
37. Gao X, Zacharek A, Grignon D, Liu H, Sakr W, Porter A, Chen Y, Honn K. 1995a. High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer. Int J Oncol 6:111117.
38. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV. 1995b. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 55:1002-1005.
39. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA. 1999. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 64:776-787.
40. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. 1997. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57:4687-4691.
41. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. 1997. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94:3320-3323.
42. Gopalkrishnan RV, Kang DC, Fisher PB. 2001. Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 189:245-256.
43. Gronberg H, Damber L, Damber JE, Iselius L. 1997. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance. Am J Epidemiol 146:552-557.
44. Halvorsen OJ, Hostmark J, Haukaas S, Hoisaeter PA, Akslen LA. 2000. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 88:416-424.
45. Huang H, Qian C, Jenkins RB, Smith DI. 1998. Fish mapping of YAC clones at human chromosomal band 7q31.2: Identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosom Cancer 21:152-159.
46. Jemal ATA, Murray T, Thun M. 2002. Cancer statistics, 2002 CA Cancer J Clin 32:23-47.
47. Jenkins RB, Qian J, Lieber MM, Bostwick DG. 1997. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531.
48. Jones PA, Laird PW. 1999. Cancer epigenetics comes of age. Nature Genet 21:163-167.
49. Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du Manoir S, Lichter P. 1995. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosom Cancer 14:267-276.
50. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. 1997. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3:402-408.
51. Knudson AG Jr. 1984. Genetic predisposition to cancer. Cancer Detect Prev 7:1-8.
52. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. 1994. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91:11733-11737.
53. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. 2000. Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression. Cancer Res 60:702-706.
54. Li LC, Zhao H, Nakajima K, Oh BR, Filho LA, Carroll P, Dahiya R. 2001. Methylation of the e-cadherin gene promoter correlates with progression of prostate cancer. J Urol 166:705-709.
55. Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF Jr, Isaacs WB, Isaacs JT, Gao AC. 1999. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 59:2329-2331.
56. Macoska JA, Powell IJ, Sakr W, Lane MA. 1992. Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. J Urol 147:1142-1146.
57. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, Pontes JE. 1994. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 54:3824-3830.
58. Makridakis NM, Reichardt JK. 2001. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev 23:24-29.
59. Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hagarth L, Kudren D, Naito K, Bergerheim US, Ekman P. 2001. Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clin Cancer Res 7:3139-3143.
60. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. 1992. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res 52:6940-6944.
61. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. 1999. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 18:1313-1324.
62. Nguyen TT, Nguyen CT, Gonzales FA, Nichols PW, Yu MC, Jones PA. 2000. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers. Prostate 43:233-242.
63. Nwosu V, Carpten J, Trent JM, Sheridan R. 2001. Heterogeneity of genetic alterations in prostate cancer: Evidence of the complex nature of the disease. Hum Mol Genet 10:2313-2318.
64. Ostrander EA, Stanford JL. 2000. Genetics of prostate cancer: Too many loci, too few genes. Am J Hum Genet 67:1367-1375.
65. Ozen M, Pathak S. 2000. Genetic alterations in human prostate cancer: A review of current literature. Anticancer Res 20:1905-1912.
66. Phillips JL, Hayward SW, Wang Y, Vasselli J, Pavlovich C, Padilla-Nash H, Pezullo JR, Ghadimi BM, Grossfeld GD, Rivera A, Linehan WM, Cunha GR, Ried T. 2001. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 61:8143-8149.
67. Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, Murphy JR, Markowitz SD, Jamison JM, Summers JL, Hamlin CR, MacLennan GT, Resnick MI, Pretlow TP, Connell CF. 2000. Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res 60:4033-4036.
68. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA, Rohr LR, Yin X, Brothman AR. 1998. Commonly occurring loss and mutation of the MX11 gene in prostate cancer. Genes Chromosom Cancer 22:295-304.
69. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. 1995. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk. Cancer Res 55:3973-3975.
70. Sakr WA, Grignon DJ, Haas GP. 1998. Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Semin Urol Oncol 16:214-220.
71. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. 1998. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 62:1425-1438.
72. Shalev M, Thompson TC, Kadmon D, Ayala G, Kernen K, Miles BJ. 2001. Gene therapy for prostate cancer. Urology 57:8-16.
73. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. 1996. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374.
74. Steiner MS, Gingrich JR. 2000. Gene therapy for prostate cancer: Where are we now? J Urol 164:1121-1136.
75. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J. 1996. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosom Cancer 17:225-233.
76. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB. 1994. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 54:3574-3579.
77. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, CannonAlbright LA. 2001. A candidate prostate cancer susceptibility gene at chromosome 17p. Nature Genet 27:172-180.
78. Tennant TR, Kim H, Sokoloff M, Rinker-Schaeffer CW. 2000. The Dunning model. Prostate 43:295-302.
79. Thompson TC, Timme TL, Park SH, Yang G, Ren C. 2000. Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 43:248-254.
80. Verhagen PC, Zhu XL, Rohr LR, Cannon-Albright LA, Tavtigian SV, Skolnick MH, Brothman AR. 2000. Microdissection, DOP-PCR, and comparative genomic hybridization of paraffin-embedded familial prostate cancers. Cancer Genet Cytogenet 122:43-48.
81. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. 1995a. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 9:401-406.
82. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. 1995b. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347.
83. Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr LR, Brothman AR. 1996. Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer [see Comments]. J Urol 155:720-725.
84. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Gronberg H, Emanuelson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J. 1998. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nature Genet 20:175-179.
85. Yang G, Truong LD, Wheeler TM, Thompson TC. 1999. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res 59:5719-5723.